ETYQA Drug Patent Profile
✉ Email this page to a colleague
When do Etyqa patents expire, and what generic alternatives are available?
Etyqa is a drug marketed by Aurobindo Pharma Ltd and is included in one NDA.
The generic ingredient in ETYQA is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Etyqa
A generic version of ETYQA was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ETYQA?
- What are the global sales for ETYQA?
- What is Average Wholesale Price for ETYQA?
Summary for ETYQA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | ETYQA at DailyMed |
Pharmacology for ETYQA
| Drug Class | Estrogen Progestin |
| Mechanism of Action | Estrogen Receptor Agonists |
US Patents and Regulatory Information for ETYQA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | ETYQA | estradiol; norethindrone acetate | TABLET;ORAL | 214729-001 | Jun 30, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurobindo Pharma Ltd | ETYQA | estradiol; norethindrone acetate | TABLET;ORAL | 214729-002 | Jun 30, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
